A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United States. Across both regions, oncologists have widely reported they have prescribed biosimilars, and with an increasing number of biosimilars submitted for approval, alongside pressures from payers and institutions to lower costs, the use of biosimilars is likely to increase. The absence of ESA biosimilars in the United States and of monoclonal antibody biosimilars for oncology across both regions presents opportunities for biosimilar manufacturers as well as considerations for companies wishing to defend against biosimilar erosion. We conducted market research with medical oncologists and hematology-oncologists in France, Germany, and the United States to gain insights on attitudes toward biosimilars, drivers and barriers to biosimilar use, and expectations for future adoption.


Related Reports

Biomarkers in Oncology | Access & Reimbursement | Detailed, Expanded Analysis: Multi-indication (US)

Biomarker-driven prescribing is paramount in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer and malignant me...

View Details

Biosimilars | Current Treatment | Oncology

In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb

View Details

Biosimilars | Access & Reimbursement | Oncology

This report is available to find out more click the link and fill out the form to get more details.

View Details

Biosimilars | Emerging Biosimilars | Oncology: Trastuzumab Biosimilars Launch Tracking (Germany) Wave 3

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimila...

View Details